These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 34088448)
1. Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Mulet X; Fernández-Esgueva M; Norte C; Zamorano L; Del Barrio-Tofiño E; Oliver A; Enferm Infecc Microbiol Clin (Engl Ed); 2021; 39(6):279-282. PubMed ID: 34088448 [TBL] [Abstract][Full Text] [Related]
2. O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones. Mulet X; García R; Gayá M; Oliver A Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):541-544. PubMed ID: 30680561 [TBL] [Abstract][Full Text] [Related]
5. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505 [TBL] [Abstract][Full Text] [Related]
6. Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. Del Barrio-Tofiño E; Sánchez-Diener I; Zamorano L; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A; J Antimicrob Chemother; 2019 Nov; 74(11):3217-3220. PubMed ID: 31430372 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337 [TBL] [Abstract][Full Text] [Related]
8. Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. García-Castillo M; Del Campo R; Morosini MI; Riera E; Cabot G; Willems R; van Mansfeld R; Oliver A; Cantón R J Clin Microbiol; 2011 Aug; 49(8):2905-10. PubMed ID: 21697331 [TBL] [Abstract][Full Text] [Related]
9. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893 [TBL] [Abstract][Full Text] [Related]
10. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM; J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350 [TBL] [Abstract][Full Text] [Related]
11. Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods. Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA J Antimicrob Chemother; 2017 Nov; 72(11):3079-3084. PubMed ID: 28961968 [TBL] [Abstract][Full Text] [Related]
12. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS. Hernández-García M; García-Castillo M; García-Fernández S; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Romano J; Pássaro L; Paixão L; López-Mendoza D; Díaz-Regañón J; Cantón R; J Antimicrob Chemother; 2021 Jan; 76(2):370-379. PubMed ID: 33099623 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. Gomis-Font MA; Cabot G; López-Argüello S; Zamorano L; Juan C; Moyá B; Oliver A J Antimicrob Chemother; 2022 Mar; 77(4):957-968. PubMed ID: 35084040 [TBL] [Abstract][Full Text] [Related]